Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07545954CT.gov DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07654400CT.gov A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07625644CT.gov Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07339059CT.gov Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07472517CT.gov DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy | — | Recruiting | — | — | — |
NCT07407933CT.gov A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07227597CT.gov A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | — | Recruiting | — | — | — |
NCT07113691CT.gov Iadademstat + SBRT With Atezo in ES-SCLC | — | Recruiting | — | — | — |
NCT07226999CT.gov Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07155174CT.gov A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 70 more trialsShow fewer
NCT06066138CT.gov A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | — | Recruiting | — | — | — |
NCT07172412CT.gov Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07106528CT.gov Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06939036CT.gov Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | — | Terminated | — | — | — |
NCT06830694CT.gov Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | — | Recruiting | — | — | — |
NCT06287775CT.gov Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06869239CT.gov Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy | — | Recruiting | — | — | — |
NCT06646276CT.gov A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | — | Recruiting | — | — | — |
NCT06717243CT.gov Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) | — | Recruiting | — | — | — |
NCT06712355CT.gov Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | — | Recruiting | — | — | — |
NCT06768307CT.gov Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06807632CT.gov A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | — | Recruiting | — | — | — |
NCT06663098CT.gov Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). | — | Recruiting | — | — | — |
NCT06719336CT.gov Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | — | Not Yet Recruiting | — | — | — |
NCT06780826CT.gov A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | — | Recruiting | — | — | — |
NCT06362252CT.gov A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | — | Recruiting | — | — | — |
NCT06429696CT.gov PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05703971CT.gov Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | — | Recruiting | — | — | — |
NCT06110572CT.gov Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | — | Recruiting | — | — | — |
NCT06077500CT.gov DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06179069CT.gov A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05652686CT.gov A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | — | Recruiting | — | — | — |
NCT05703997CT.gov FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | — | Not Yet Recruiting | — | — | — |
NCT05468489CT.gov To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | — | Active Not Recruiting | — | — | — |
NCT05595460CT.gov Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | — | Active Not Recruiting | — | — | — |
NCT05797493CT.gov Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05361395CT.gov First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | — | Active Not Recruiting | — | — | — |
NCT05142696CT.gov A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | — | Active Not Recruiting | — | — | — |
NCT05253053CT.gov To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05191797CT.gov Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05224141CT.gov Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | — | Active Not Recruiting | — | — | — |
NCT04919382CT.gov Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06771518CT.gov Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | — | Recruiting | — | — | — |
NCT04308785CT.gov A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05091567CT.gov A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04923776CT.gov Liver Directed RT + Chemo-immunotherapy for ES-SCLC | — | Terminated | — | — | — |
NCT04696575CT.gov Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04560972CT.gov LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04631029CT.gov Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | — | Completed | — | — | — |
NCT04487756CT.gov Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer | — | Completed | — | — | — |
NCT04402788CT.gov Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | — | Recruiting | — | — | — |
NCT04610684CT.gov Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | — | Terminated | — | — | — |
NCT04696939CT.gov Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT04665856CT.gov Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04622228CT.gov Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04471727CT.gov A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | — | Active Not Recruiting | — | — | — |
NCT04373369CT.gov Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04422210CT.gov A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | — | Terminated | — | — | — |
NCT04462276CT.gov Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | — | Completed | — | — | — |
NCT04334941CT.gov Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | — | Active Not Recruiting | — | — | — |
NCT04730999CT.gov Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT04101357CT.gov Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | — | Terminated | — | — | — |
NCT04256421CT.gov A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04221529CT.gov Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide | — | Completed | — | — | — |
NCT04253145CT.gov Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | — | Unknown | — | — | — |
NCT04028050CT.gov A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03811002CT.gov Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | — | Active Not Recruiting | — | — | — |
NCT05055947CT.gov Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05055999CT.gov Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03830918CT.gov Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03782207CT.gov A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice | — | Active Not Recruiting | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03540420CT.gov Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03262454CT.gov Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC | — | Unknown | — | — | — |
NCT03232593CT.gov A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | — | Completed | — | — | — |
NCT03041311CT.gov Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | — | Completed | — | — | — |
NCT03059667CT.gov Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02763579CT.gov A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | — | Completed | — | — | — |
NCT02748889CT.gov Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Washington University School of Medicine | P3 | BB · 65 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →